[Role of inflammation on renal anaemia].
It is well-known the central role of inflammation in the inhibition of erythropoiesis and iron availability in chronic kidney disease (CKD) patients with erythropoietin (EPO)-resistant anaemia. This inflammatory action is mediated by suppressive cytokines (i.e. IL-6, TNF-, INF-) inhibiting differentiation and proliferation activities of erythroid cells in the EPO-indipendent phase of erythropoiesis and stimulating hepcidin production for iron retention in reticulo-endothelial system and enterocytes. EPO resistance is associated with adverse outcomes, such as cardiovascular disease, faster progression to end stage renal disease and mortality. Treatment of the causes of EPO hyporesponsiveness including chronic inflammation results in an improvement of anaemia and a reduction in EPO requirements.